Trends in ototoxicity monitoring among cisplatin-treated patients with cancer
Journal of Cancer Survivorship · 2025
DOI: 10.1007/s11764-024-01586-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Survivorship, 2025. Verfasst von David S Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis,…. Hauptthemen laut MEDLINE: Cisplatin, Ototoxicity, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Institute of Deafness and Other Communication Disorders (NIDCD).
Abstract (Originalsprache)
PURPOSE: This study aims to characterize patterns in ototoxicity monitoring and identify potential barriers to audiologic follow-up. METHODS: We performed a single-institution retrospective cohort study on adult (≥ 18 years old) cancer patients treated with cisplatin from January 2014 to September 2021. Our primary outcomes were rates of baseline and post-treatment audiograms at the following time points: 3, 6, 12, and greater than 12 months. Time-to-event analyses were performed to describe additional insights to ototoxicity monitoring patterns. RESULTS: Nine hundred fifty-five patients with cancer were included for analysis. The most common primary cancer sites were head and neck (64%), followed by cervical (24%). Three hundred seventy-three patients (39%) underwent baseline audiometric assessment, 38 patients (4%) received audiologic evaluation during chemotherapy, and 346 patients (36%) obtained at least one post-treatment audiogram. Audiologic follow-up was greatest within 3 months of completing chemotherapy (26%), but this tapered dramatically to less than 10% at every other post-treatment time point. Patients with head and neck cancer achieved higher rates of audiologic follow-up at every time point than patients with non-head and neck cancer except for during treatment. CONCLUSIONS: Ototoxicity monitoring is an inconsistent practice, particularly during chemotherapy and for long-term surveillance of hearing loss. Patients with non-head and neck cancer may be at increased risk for loss of audiologic follow-up. IMPLICATIONS FOR CANCER SURVIVORS: Cisplatin ototoxicity is a common occurrence that can be effectively managed with auditory rehabilitation. Therefore, referrals to audiology and counseling on treatment-related ototoxicity are recommended throughout chemotherapy and cancer survivorship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA. david.s.lee@wustl.edu.
- Division of Adult Audiology, Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
- Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Förderung
- National Institute of Deafness and Other Communication Disorders (NIDCD)
Zitieren
APA
Lee, D. S., Travis, E. Y., Wong, S. K., Munyemana, M. A., Mueller, L., Rowling, C. C., Rich, J. T., Pipkorn, P., Puram, S. V., Jackson, R. S., Adkins, D. R., Oppelt, P., Thorstad, W. L., Wick, C. C., Zevallos, J. P., McClannahan, K., & Mazul, A. L. (2025). Trends in ototoxicity monitoring among cisplatin-treated patients with cancer. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-024-01586-3
Vancouver
Lee DS, Travis EY, Wong SK, Munyemana MA, Mueller L, Rowling CC, et al. Trends in ototoxicity monitoring among cisplatin-treated patients with cancer. Journal of Cancer Survivorship. 2025. doi:10.1007/s11764-024-01586-3
BibTeX
@article{Lee2025,
author = {Lee, David S and Travis, Emma Y and Wong, Susan K and Munyemana, Marie-Ange and Mueller, Lauren and Rowling, Cathryn Collopy and Rich, Jason T and Pipkorn, Patrik and Puram, Sidharth V and Jackson, Ryan S and Adkins, Douglas R and Oppelt, Peter and Thorstad, Wade L and Wick, Cameron C and Zevallos, Jose P and McClannahan, Kate and Mazul, Angela L},
title = {Trends in ototoxicity monitoring among cisplatin-treated patients with cancer},
journal = {Journal of Cancer Survivorship},
year = {2025},
doi = {10.1007/s11764-024-01586-3}
}
EUVIMED